Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Hypertrophic cardiomyopathy in 2012.

Literature DB >> 22431884

Hypertrophic cardiomyopathy in 2012.

Carolyn Y Ho¹.

Abstract

Entities: Chemical Disease Gene Species

Mesh：

Year: 2012 PMID： 22431884 PMCID： PMC3328186 DOI： 10.1161/CIRCULATIONAHA.110.017277

Source DB: PubMed Journal: Circulation ISSN： 0009-7322 Impact factor: 29.690

× No keyword cloud information.

34 in total

1. Clinical profile and significance of delayed enhancement in hypertrophic cardiomyopathy.

Authors: Martin S Maron; Evan Appelbaum; Caitlin J Harrigan; Jacki Buros; C Michael Gibson; Connie Hanna; John R Lesser; James E Udelson; Warren J Manning; Barry J Maron
Journal: Circ Heart Fail Date: 2008-06-23 Impact factor: 8.790

2. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy.

Authors: Kevin M Harris; Paolo Spirito; Martin S Maron; Andrey G Zenovich; Francesco Formisano; John R Lesser; Shannon Mackey-Bojack; Warren J Manning; James E Udelson; Barry J Maron
Journal: Circulation Date: 2006-07-10 Impact factor: 29.690

3. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction.

Authors: Martin S Maron; Iacopo Olivotto; Andrey G Zenovich; Mark S Link; Natesa G Pandian; Jeffery T Kuvin; Stefano Nistri; Franco Cecchi; James E Udelson; Barry J Maron
Journal: Circulation Date: 2006-11-06 Impact factor: 29.690

4. Bethesda Conference #36 and the European Society of Cardiology Consensus Recommendations revisited a comparison of U.S. and European criteria for eligibility and disqualification of competitive athletes with cardiovascular abnormalities.

Authors: Antonio Pelliccia; Douglas P Zipes; Barry J Maron
Journal: J Am Coll Cardiol Date: 2008-12-09 Impact factor: 24.094

5. Device complications and inappropriate implantable cardioverter defibrillator shocks in patients with hypertrophic cardiomyopathy.

Authors: G Lin; R A Nishimura; B J Gersh; D Phil; S R Ommen; M J Ackerman; P A Brady
Journal: Heart Date: 2009-03-11 Impact factor: 5.994

6. Long-term survival after cardiac arrest in hypertrophic cardiomyopathy.

Authors: Barry J Maron; Tammy S Haas; Kevin M Shannon; Adrian K Almquist; James S Hodges
Journal: Heart Rhythm Date: 2009-03-11 Impact factor: 6.343

7. Myofilament protein gene mutation screening and outcome of patients with hypertrophic cardiomyopathy.

Authors: Iacopo Olivotto; Francesca Girolami; Michael J Ackerman; Stefano Nistri; J Martijn Bos; Elisabetta Zachara; Steve R Ommen; Jeanne L Theis; Rachael A Vaubel; Federica Re; Corinna Armentano; Corrado Poggesi; Francesca Torricelli; Franco Cecchi
Journal: Mayo Clin Proc Date: 2008-06 Impact factor: 7.616

8. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy.

Authors: Barry J Maron; Paolo Spirito; Win-Kuang Shen; Tammy S Haas; Francesco Formisano; Mark S Link; Andrew E Epstein; Adrian K Almquist; James P Daubert; Thorsten Lawrenz; Giuseppe Boriani; N A Mark Estes; Stefano Favale; Marco Piccininno; Stephen L Winters; Massimo Santini; Sandro Betocchi; Fernando Arribas; Mark V Sherrid; Gianfranco Buja; Christopher Semsarian; Paolo Bruzzi
Journal: JAMA Date: 2007-07-25 Impact factor: 56.272

Review 9. Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice.

Authors: P Elliott; P Spirito
Journal: Heart Date: 2008-07-24 Impact factor: 5.994

10. Relevance of coronary microvascular flow impairment to long-term remodeling and systolic dysfunction in hypertrophic cardiomyopathy.

Authors: Iacopo Olivotto; Franco Cecchi; Roberto Gistri; Roberto Lorenzoni; Giampaolo Chiriatti; Francesca Girolami; Francesca Torricelli; Paolo G Camici
Journal: J Am Coll Cardiol Date: 2006-03-07 Impact factor: 24.094

18 in total

Review 1. The genetic basis of hypertrophic cardiomyopathy in cats and humans.

Authors: Mark D Kittleson; Kathryn M Meurs; Samantha P Harris
Journal: J Vet Cardiol Date: 2015-12 Impact factor: 1.701

2. Family Relationships Associated With Communication and Testing for Inherited Cardiac Conditions.

Authors: Lisa L Shah; Sandra Daack-Hirsch; Anne L Ersig; Anthony Paik; Ferhaan Ahmad; Janet Williams
Journal: West J Nurs Res Date: 2018-12-12 Impact factor: 1.967

3. Factors Associated with Uptake of Genetics Services for Hypertrophic Cardiomyopathy.

Authors: Amirah Khouzam; Andrea Kwan; Samantha Baxter; Jonathan A Bernstein
Journal: J Genet Couns Date: 2015-01-08 Impact factor: 2.537

Review 4. Risk stratification in hypertrophic cardiomyopathy.

Authors: S Marrakchi; I Kammoun; E Bennour; L Laroussi; S Kachboura
Journal: Herz Date: 2018-04-25 Impact factor: 1.443

Review 5. Targeting the ubiquitin-proteasome system in heart disease: the basis for new therapeutic strategies.

Authors: Oliver Drews; Heinrich Taegtmeyer
Journal: Antioxid Redox Signal Date: 2014-10-01 Impact factor: 8.401

6. Cardiomyopathy mutations in the tail of β-cardiac myosin modify the coiled-coil structure and affect integration into thick filaments in muscle sarcomeres in adult cardiomyocytes.

Authors: Marcin Wolny; Melanie Colegrave; Lucy Colman; Ed White; Peter J Knight; Michelle Peckham
Journal: J Biol Chem Date: 2013-09-18 Impact factor: 5.157